Viewing Study NCT06632951

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:53 PM
Ignite Modification Date: 2026-03-31 @ 4:57 AM
Study NCT ID: NCT06632951
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-08-11
First Post: 2024-10-08
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
Sponsor: AbbVie
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Urothelial Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Urothelial Carcinoma View
None Metastatic Urothelial Carcinoma View
None Docetaxel View
None Paclitaxel View
None Gemcitabine View
None Livmoniplimab View
None Budigalimab View
None ABBV-181 View
None ABBV-151 View
None Cancer View
None LIVIGNO-3 View